Results 71 to 80 of about 30,146 (272)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity

Biochemistry and Biophysics Reports, 2020
Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19.
Markus Fischer, Meike Luck, Maximilian Werle, Holger A. Scheidt, Peter Müller   +4 more
doaj   +1 more source

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]

, 2015
Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core   +1 more source

Molecular imprinting for neurology: Materials, applications, and limitations

Ibrain, EarlyView.
Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma, Yingqi Ma, Claudia Marino, Alessandro Poma   +3 more
wiley   +1 more source

The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model

Journal of Clinical Laboratory Analysis, EarlyView.
Momelotinib, a selective small‐molecule inhibitor of JAK1/2 and the bone morphogenic protein receptor kinase activin A receptor type I (ACVR1), exerts its effects by inhibiting the overactivation of the BMP/ACVR1/SMAD signaling pathway. This inhibition reduces hepcidin production in hepatocytes, and reduces inflammation, aberrant cytokine signaling ...
Yue Zhang, Huiqin Zhang, Naibo Hu, Liping Yang, Yumei Liu, Liyan Yang, Xifeng Dong, Huaquan Wang   +7 more
wiley   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4‐year‐old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose ...
Alison Laxer, Morris Edelman, Julie Gallagher, Benjamin Sahn   +3 more
wiley   +1 more source

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I

Haematologica, 2013
COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W.N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson-Viitanen, William Sun, Victor Sandor, Hagop M. Kantarjian   +22 more
doaj   +1 more source

Interferon‐gamma blocking as a promising treatment for severe liver dysfunction in secondary hemophagocytic lymphohistiocytosis after liver transplantation

JPGN Reports, EarlyView.
Abstract Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome that can occur after solid organ transplantation but remains underrecognized in this setting. The diagnosis is often delayed due to overlapping clinical manifestations with infection, rejection, or malignancy, and management becomes particularly ...
Chen Chen, Tao Zhou, Jing Jin, Yi Luo, Lijing Shen, Qiang Xia, Yongbing Qian   +6 more
wiley   +1 more source

STAT3 the oncogene - still eluding therapy? [PDF]

, 2015
The STAT family of transcription factors (signal transducers and activators of transcription) transduce signals from cytokine receptors to the nucleus, where STAT dimers bind to DNA and regulate transcription.
Akira, Alas, Amin, Badve, Barbieri, Bendell, Berclaz, Bhargava, Boehm, Bromberg, Bromberg, Buettner, Cao, Chakraborty, Chan, Chase, Choi, Chung, Claudinon, Dabir, Dauer, Debnath, Dechow, Demaria, Dercamp, Dhanik, Dias, Duong, Dvorak, Gao, Garcia, Garcia, Goodwin, Graham, Hao, Hedvat, Hemmann, Hevehan, Ho, Hu, Huang, Huang, Huang, Iwamaru, Kang, Kortylewski, Kunigal, Lee, Lee, Levine, Li, Lin, Liu, Maritano, Mesa, Migone, Miklossy, Miyoshi, Nagel-Wolfrum, Nefedova, Nguyen, Ogura, Park, Park, Pilati, Pranada, Regis, Ren, Schuringa, Schust, Schust, Sen, Sethi, Siddiquee, Song, Spitzner, Starr, Takeda, Tell, Timofeeva, Timofeeva, Turkson, Turkson, Viguier, Vinkemeier, Watson, Weber-Nordt, Wong, Xu, Xu, Xu, Yoo, Yoshikawa, Zhang, Zhang, Zhang   +95 more
core   +2 more sources